4843-98-5

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-Hydroxypyrazole is used as a building block for the synthesis of pharmaceuticals and agrochemicals, leveraging its reactivity and stability to create bioactive compounds with potential applications in medicine and agriculture.
Used in Organic Synthesis:
4-Hydroxypyrazole is used as a reagent in the synthesis of organic compounds, facilitating the formation of a variety of derivatives due to its hydroxyl group.
Used in Coordination Chemistry:
4-Hydroxypyrazole is utilized as a ligand in coordination chemistry, contributing to the structural and functional properties of metal complexes.

InChI:InChI=1/C3H4N2O/c6-3-1-4-5-2-3/h1-2,6H,(H,4,5)

Upstream product

• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 23705-85-3 dimethyl 4-hydroxy-1H-pyrazole-3,5-dicarboxylate 
• 763120-58-7 1H-pyrazole-4-boronic acid 

Relevant academic research and scientific papers

Coordination Polymers as a Functional Material for the Selective Molecular Recognition of Nitroaromatics and ipso-Hydroxylation of Arylboronic Acids

We report the synthesis and structural characterization of two coordination polymers (CPs), namely; [{Zn(L)(DMF)4} ? 2BF4]α (1) and [{Cd(L)2(Cl)2} ? 2H2O]α (2) (where L=N2,N6-di(pyridin-4-yl)naphthalene-2,6-dicarboxamide). Crystal packing of 1 reveals the existence of channels running along the b- and c-axis filled by the ligated DMF and lattice anions, respectively. Whereas, crystal packing of 2 reveals that the metallacycles of each 1D chain are intercalating into the groove of adjacent metallacycles resulting in the stacking of 1D loop-chains to form a sheet-like architecture. In addition, both 1 and 2 were exploited as multifunctional materials for the detection of nitroaromatic compounds (NACs) as well as a catalyst in the ipso-hydroxylation of aryl/heteroarylboronic acids. Remarkably, 1 and 2 showed high fluorescence stability in an aqueous medium and displayed a maximum 88% and 97% quenching efficiency for 4-NPH, respectively among all the investigated NACs. The mechanistic investigation of NACs recognition suggested that the fluorescence quenching occurred via electron as well as energy transfer process. Furthermore, the ipso-hydroxylation of aryl/heteroarylboronic acids in presence of 1 and 2 gave up to 99% desired product yield within 15 min in our established protocol. In both cases, 1 and 2 are recyclable upto five cycles without any significant loss in their efficiency.

Nickel-catalyzed oxidative hydroxylation of arylboronic acid: Ni(HBTC)BPY MOF as an efficient and ligand-free catalyst to access phenolic motifs

A straightforward and mild oxidative ipso-hydroxylation of arylboronic acids has been achieved using a simple and non-noble metal, nickel-based reusable heterogeneous catalyst Ni(HBTC)BPY MOF (HBTC = benzene-1,3,5-tricarboxylate, BPY = 4,4′-bipyridine) in the presence of benign hydrogen peroxide as an oxidant under ambient reaction condition. The Ni(HBTC)BPY MOF exhibits excellent catalytic activity towards the formation of phenols from diverse arylboronic acids within short time and can be reused up to five times without any notable loss in its activity as well as shown high functional group tolerance even in the presence of sensitive functionalities and useful to achieve hydroxyl group in heterocycles.

A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity

A novel series of glucagon receptor antagonists has been discovered. These pyrazole ethers and aminopyrazoles have lower molecular weight and increased polarity such that the molecules fall into better drug-like property space. This work has culminated in

8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS

The present invention is related to compound of the formula (I): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein A is a 6-membered heteroaryl having from 1 to 3 heteroatoms, each independently selected from N or O and the other substituents are defined as in the claims.

SELECTIVE BETA3 ADRENERGIC AGONISTS

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating Type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of formula (I) or a pharmaceutically acceptable salt thereof. The variables of formula (I) have the meanings defined herein.

SELECTIVE BETA3 ADRENERGIC AGONISTS

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: